Skip to main content

Table 2 Correlations between ULBP-3, ULBP-4 and ULBP-5 expression and well-established prognostic factors.

From: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

  Total ULBP3    ULBP4    ULBP5
    Low   High   Low   High   Low   High  
  N % N % N % N % N % N % N %
Age               
< 40
40-50
50-60
> = 60
48
145
132
249
8.4
25.3
23.0
43.4
25
84
68
128
8.2
27.5
22.3
42.0
11
24
22
55
9.8
21.4
19.6
49.1
29
91
86
164
7.8
24.6
23.2
44.3
15
33
30
49
11.8
26.0
23.6
38.6
38
119
103
185
8.5
26.7
23.1
41.6
3
9
12
23
6.4
19.1
25.5
48.9
Grade               
I
II
III
80
282
203
14.2
49.9
35.9
45
160
96
15.0
53.2
31.9
10
43
57
9.1
39.1
51.8
51
181
134
13.9
49.5
36.6
13
67
43
10.6
54.5
35.0
62
219
157
14.2
50.0
35.8
2
21
23
4.3
45.7
50.0
Histological type               
Ductal
Lobular
513
53
90.6
9.4
281
20
93.4
6.6
102
8
92.7
7.3
330
37
89.9
10.1
113
10
91.9
8.1
396
43
90.2
9.8
43
3
93.5
6.5
T-status               
T1
T2
T3/4
211
272
72
38.0
49.0
13.0
113
142
39
38.4
48.3
13.3
40
54
17
36.0
48.6
15.3
118
180
60
33.0
50.3
16.8
57
61
6
46.0
49.2
4.8
159
209
64
36.8
48.4
14.8
19
26
2
40.4
55.3
4.3
N-status               
N0
N1-3
307
250
55.1
44.9
158
135
53.9
46.1
61
49
55.5
44.5
193
170
53.2
46.8
66
55
54.5
45.5
237
196
54.7
45.3
24
21
53.3
46.7
ER-status               
Negative
Positive
203
337
37.6
62.4
113
178
38.8
61.2
37
73
33.6
66.4
135
222
37.8
62.2
43
80
35.0
65.0
152
278
35.3
64.7
21
25
45.7
54.3
PgR-status               
Negative
Positive
223
313
41.6
58.4
130
159
45.0
55.0
42
68
38.2
61.8
141
215
39.6
60.4
51
72
41.5
58.5
158
267
37.2
62.8
26
21
55.3
44.7
Her2-status               
Overexpression -
Overexpression +
378
44
80.9
19.1
207
24
89.6
10.4
82
10
89.1
10.9
256
33
88.6
11.4
93
6
93.9
6.1
311
32
90.7
9.3
35
6
85.4
14.6
Local Therapy               
MAST-RT
MAST+RT
BCS-RT
BCS+RT
223
108
5
238
38.9
18.8
0.9
41.5
116
56
3
130
38.0
18.4
1.0
42.6
43
24
1
44
38.4
21.4
0.9
39.3
141
86
1
142
38.1
23.2
0.3
38.4
46
14
3
64
36.2
11.0
2.4
50.4
165
94
4
182
37.1
21.1
0.9
40.9
24
3
0
20
51.1
6.4
0.0
42.6
Systemic therapy               
CT alone
HT alone
CT&HT
None
112
75
18
369
19.5
13.1
3.1
64.3
65
32
10
198
21.3
10.5
3.3
64.9
23
10
2
77
20.5
8.9
1.8
68.8
81
52
13
224
21.9
14.1
3.5
60.5
20
16
1
90
20.3
12.6
0.8
70.9
93
60
11
281
20.9
13.5
2.5
63.1
8
5
1
33
17.0
10.6
2.1
70.2
Total 574 100 305 100 112 100 370 100 127 100 445 100 47 100
  1. Missing values are not shown.
  2. AbbreviationsN number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.